Glass M W, Schultz A M, Mathieson B J, Lawrence D, Wescott S, Koff W C
Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Vaccine. 1990 Aug;8(4):413-4. doi: 10.1016/0264-410x(90)90127-8.
In this short review of the three-day meeting on AIDS vaccine development where numerous scientific advances were described for the first time, it is nearly impossible to capture all of the highlights. Thus, areas such as advances in vaccine adjuvant development, standardized challenge pools for vaccine testing, novel approaches with retroviral vectors for construction of target cells for cellular immune assays, summaries from all of the international AIDS vaccine development programmes, and other topics which were covered at the meeting are not discussed above. In closing the meeting, W. Koff (NIAID) noted that 1989 represented the turning point for AIDS vaccine development, that pessimism had given way to cautious optimism, and that the fundamental focus had changed from 'if a vaccine could be developed' to 'when'. While several challenges still remain in the path toward development of a safe and effective vaccine, the meeting served both to focus the direction of the research agenda for the next year and to build new and stronger collaborations among the international network of scientists dedicated to the common goal of developing a safe and effective AIDS vaccine.
在本次对为期三天的艾滋病疫苗开发会议的简短回顾中，会上首次介绍了众多科学进展，几乎不可能涵盖所有亮点。因此，诸如疫苗佐剂开发的进展、用于疫苗测试的标准化攻击毒株库、用于构建细胞免疫测定靶细胞的逆转录病毒载体新方法、所有国际艾滋病疫苗开发项目的总结以及会议涵盖的其他主题等领域，上文未作讨论。会议闭幕时，美国国立过敏与传染病研究所的W. 科夫指出，1989年是艾滋病疫苗开发的转折点，悲观情绪已被谨慎乐观所取代，根本重点已从“能否开发出疫苗”转变为“何时开发出疫苗”。虽然在开发安全有效的疫苗的道路上仍存在若干挑战，但本次会议既为确定明年的研究议程方向起到了作用，也在致力于开发安全有效的艾滋病疫苗这一共同目标的国际科学家网络之间建立了新的、更强大的合作关系。
